San Diego-based Illumina is commercializing three new products aimed at a better understanding of the molecular mechanisms that give rise to cancer. Illumina's DASL Assay is designed to profile expression in degraded RNA, such as that found in formalin-fixed paraffin embedded samples. At the Dana-Farber Cancer Institute researchers are using whole-genome DASL profiling to identify molecular profiles associated with chemotherapy resistance in ovarian cancer.
"We have a significant number of archived ovarian cancer samples, and this new approach has provided me with a way to finally access the information in these invaluable samples," said Harvard's Dr. John Quackenbush. "The DASL assay gives us the ability to obtain consistent, high-quality data from FFPE samples and has opened-up new avenues of investigation that were not previously available to us."
- check out the press release
- read the story in Forbes
Related Articles:
Illumina focuses on molecular diagnostics. Illumina report
Four companies lead genome sequencing race. Illumina report
Illumina to buy Solexa for $600M. Illumina report